Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.01 EUR
Change Today 0.00 / 0.00%
Volume 0.0
DU8 On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Frankfurt
As of 3:07 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

genetic technologies ltd (DU8) Snapshot

Open
€0.01
Previous Close
€0.01
Day High
€0.01
Day Low
€0.0090
52 Week High
02/18/15 - €0.07
52 Week Low
10/6/14 - €0.0030
Market Cap
17.2M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENETIC TECHNOLOGIES LTD (DU8)

genetic technologies ltd (DU8) Related Bloomberg News

View More Bloomberg News

genetic technologies ltd (DU8) Related Businessweek News

No Related Businessweek News Found

genetic technologies ltd (DU8) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders. The company also provides DNA based tests comprising peace of mind paternity, legal paternity, antenatal DNA, deceased estate, DNA profiling, grandparent, immigration, sibling, twins, and Y-chromosome DNA tests. In addition, it offers DNA testing, canine health register, forensics, and breed identification services to animals. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited is headquartered in Fitzroy, Australia.

genetic technologies ltd (DU8) Top Compensated Officers

Chief Executive Officer, Chief Operating Offi...
Total Annual Compensation: A$14.4K
President of Phenogen Sciences Inc.
Total Annual Compensation: A$299.8K
Director of Global Licensing & Intellectual P...
Total Annual Compensation: A$140.4K
Scientific Director
Total Annual Compensation: A$125.7K
Quality and Business Operations Director
Total Annual Compensation: A$98.7K
Compensation as of Fiscal Year 2014.

genetic technologies ltd (DU8) Key Developments

Genetic Technologies Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015

Genetic Technologies Limited reported audited consolidated earnings results for the year ended June 30, 2015. Revenue from continuing operations - genetic testing services was AUD 2,011,918 against AUD 4,564,280 a year ago. Loss from continuing operations before income tax expense was AUD 8,810,170 against AUD 10,134,469 a year ago. Loss for the year attributable to owners of the company was AUD 8,810,170 or 0.82 cents per basic and diluted share against AUD 10,125,197 or 1.76 cents per basic and diluted share a year ago. Net cash flows used in operating activities was AUD 9,691,528 against AUD 10,987,088 a year ago. Purchase of property, plant and equipment was AUD 192,592 against AUD 47,917 million a year ago.

Genetic Technologies Limited Appoints Brian Manuel as Joint Company Secretary

Genetic Technologies Limited announced the appointment of Mr. Brian Manuel as Joint Company Secretary, effective immediately. Mr. Manuel joined the company as Chief Financial Officer on 15 June 2015. He is a Fellow Chartered Accountant and a Fellow of the Governance Institute of Australia. Of his 25 plus years of experience, more than a decade has been at the CFO level for companies listed on the ASX including the Biotech Company Cellestis Ltd, as the CFO and Company Secretary until its acquisition in 2011. He brings broad business acumen to the company in addition to his strong foundation in finance, IT and corporate governance.

Genetic Technologies Limited Appoints Brian Manuel as Chief Financial Officer

Genetic Technologies Limited announced the appointment of Mr. Brian Manuel as Chief Financial Officer, effective June 15, 2015. Mr. Manuel is a Fellow Chartered Accountant and a Fellow of the Governance Institute of Australia. Of his 25 plus years of experience, more than a decade has been at the CFO level for companies listed on the ASX including the Biotech Company Cellestis Ltd, as the CFO and Company Secretary until its acquisition in 2011.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DU8:GR €0.01 EUR 0.00

DU8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $35.06 USD -0.69
Sonic Healthcare Ltd A$20.29 AUD +0.55
View Industry Companies
 

Industry Analysis

DU8

Industry Average

Valuation DU8 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECHNOLOGIES LTD, please visit www.gtglabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.